Survival of patients with epithelial ovarian cancer, results of the hospital-based cancer registry of the National Cancer Institute (2005-2014)
DOI:
https://doi.org/10.35509/01239015.36Keywords:
Carcinoma, Ovarian Epithelial, Histology, Survival, Hospital-based cancer registry, ColombiaAbstract
Aims To provide demographical and clinical characteristics and estimations of 3-year overall survival of epithelial ovarian cancer (EOC) patients treated at the Colombian National Cancer Institute (INC) between 2005 and 2014.
Methods All 783 patients first treated at INC for EOC in the three periods: (2005-2008, 2009-2011, 2012-2014), without a prior cancer diagnosis, were included in this study. Follow-up was realized by cross-linkage with governmental databases using person identification numbers. Probability of surviving 36 months since the date of entry at INC was estimated using Kaplan–Meier methods, using the log-rank test to evaluate differences between groups. We used multivariate Cox proportional hazard models to evaluate the relative effect of age, clinical stage, histological subtype and treatment first on survival.
Results The overall survival probability at 36 months was 56.5% (95% CI: 53.0, 60.0), which was stable over time. Advanced age and clinical stage significantly affected 3-year overall survival, being 49.5% (95% CI: 43.4, 55.6) for age > 59, 21.9% (95% CI: 14.7, 29.2) for stage IV disease and 56.3% (95% CI: 37.5, 54.3) for serous tumors. Hazard ratios were significantly higher for patients aged 59 and over (HR 1.54 (95%CI 1.04-2.27)) and advanced stage cancers (HR 13.47 (95%CI 7.92-22.92)), whereas patients with surgery plus chemotherapy had a strongly reduced risks compared to other treatments (HR 0.84 (95%CI 0.52-1.36)).
Conclusions Survival of epithelial ovarian cancer was stable over time, with a variation according to age, clinical stage and first treatment.
Author Biographies
Constanza Pardo, Instituto Nacional de Cancerología
Grupo Vigilancia Epidemiológica del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia
Lina María Trujillo , Instituto Nacional de Cancerología
Grupo Ginecología Oncológica, Instituto Nacional de Cancerología, Bogotá, Colombia
Lina Angélica Buitrago , Instituto Nacional de Cancerología
Grupo Área Análisis de Datos, Instituto Nacional de Cancerología, Bogotá, Colombia
Esther de Vries , Pontificia Universidad Javeriana
Departamento de Epidemiología Clínica y Bioestadística, Pontificia Universidad Javeriana, Bogotá, Colombia
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBO-CAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Pardo C, Cendales R. Incidencia, mortalidad y prev-alencia de cáncer en Colombia, 2007-2011. Primera edición. Bogotá, D.C.: Instituto Nacional de Cancer-ología; 2015.
Spencer RJ, Rice LW, Ye C, Woo K, Uppal S. Dispari-ties in the allocation of research funding to gyneco-logic cancers by Funding to Lethality scores. Gynecol Oncol. 2019;152(1):106-11. Article in press. Available online 4 November 2018.
National Cancer Institute. Surveillance, Epidemiolo-gy, and End Results Program (SEER) 18 2008-2014. Di-sponible en: https://seer.cancer.gov/statfacts/html/ovary.html. Acceso 14/Diciembre/ 2018
Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23(Suppl 10): x111-7.
Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, et al. The histology of ovarian cancer: world-wide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017;144(2):405-13.
Chang LC, Huang CF, Lai MS, Shen LJ, Wu FL, Cheng WF. Prognostic factors in epithelial ovarian cancer: A pop-ulation-based study. PLoS ONE. 2018;13(3): e0194993.
Ministerio de Salud y Protección Social. Boletín del aseguramiento en salud. Dirección de Regulación de la Operación del Aseguramiento en Salud, Riesgos Lab-orales y Pensiones. Boletín No. 1. Bogotá, D.C.: MinSa-lud; 2017. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VP/DOA/boletin-aseguramiento-i-trimestre-2017.pdf
Instituto Nacional de Cancerología. Registro institucio-nal de cáncer [Bases de datos]. Bogotá: INC; 2018.
Registraduría Nacional del Estado Civil. Manual de usuario del aplicativo de expedición de certificados de vigencia de cédula. Registraduría Nacional del Es-tado Civil; 2012.
Pardo C, de Vries E, Acero D, Murillo R. Vigilancia de la supervivencia global por cáncer en Colombia: utili-dad de los registros rutinarios. Rev Colomb Cancerol. 2015;19(2):81-9.
Pardo C, de Vries E. Supervivencia global de pacientes con cáncer en el Instituto Nacional de Cancerología (INC). Rev Colomb Cancerol. 2017;21(1):12-8.
Pardo C, de Vries E. Breast and cervical cancer sur-vival at Instituto Nacional de Cancerología, Colombia. Colomb Med (Cali). 2018;49(1):102-8.
Kurman RJ, International Agency for Research on Can-cer, World Health Organization. WHO Classification of tumours of females reproductive organs. In: WHO Classification of tumours, 4th Edition, volume 6. Lyon: International Agency for Research on Cancer; 2014.
World Health Organization. International classifica-tion of diseases for oncology ICD-O-3. WHO, Interna-tional Agency for Research on Cancer; 2003.
R Core Team. R: A language and environment for sta-tistical computing. R Foundation for Statistical Com-puting, Vienna, Austria; 2018.
Chen JG, Chen HZ, Zhu J, Yang YL, Zhang YH, Huang PX, et al. Cancer survival in patients from a hospital-based cancer registry, China. J Cancer. 2018;9(5):851-60.
Wright JD, Chen L, Hou JY, Burke WM, Tergas AI, Ananth CV, et al. Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer. Ob-stet Gynecol. 2017;130(3):545-53.
Lee JY, Kim S, Kim YT, Lim MC, Lee B, Jung KW, et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018;18(1):601.
de Vries E, Karim-Kos HE, Janssen-Heijnen ML, Soer-jomataram I, Kiemeney LA, Coebergh JW. Explana-tions for worsening cancer survival. Nat Rev Clin On-col. 2010;7(1):60-3.
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-96.
González M, Barrera CA, Castillo JS. Cáncer epitelial avanzado de ovario en un grupo de pacientes colombi-anas. Rev Colomb Cancerol [internet]. 2013;17(4):142-8.
American Cancer Society. Cancer Facts & Figures 2015. Special Section: Ovarian Cancer. Atlanta: Amer-ican Cancer Society; 2018.
Dahm-Kahler P, Palmqvist C, Staf C, Holmberg E, Jo-hannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol. 2016;142(2):211–6.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
